Brought to you by 
AGI Therapeutics brings in €9.5mm in Series A round
04 Sep 2012
Executive Summary
AGI Therapeutics Ltd. (develops treatments for gastrointestinal disorders) raised €9.5mm ($11.3mm) in a Series A financing led by ACT Venture Capital, which contributed €3.5mm. Other participants included Seroba BioVentures, Delta Partners, and Merlin Biomed Group.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AGI Therapeutics brings in €9.5mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice